S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC
Esophageal Squamous Cell Carcinoma
DRUG: S1 combined with cisplatin
Progression Free Survival, from the first cycle of treatment (day one) to two month after the last cycle
Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC